E76.0
Mucopolysaccharidosis, type I
Clinical Classification Guidelines
Medical Intelligence & Overview
Mucopolysaccharidosis type I (MPS I) is an inherited disorder caused by a deficiency of certain enzymes that are necessary to break down complex sugars called mucopolysaccharides. This buildup leads to progressive damage in various parts of the body, including the bones, joints, heart, and respiratory system. The severity and specific symptoms can vary widely among individuals. MPS I is classified into three forms: Hurler syndrome (most severe), Hurler-Scheie syndrome (intermediate), and Scheie syndrome (mild). Early diagnosis and treatment are crucial to managing the condition and improving quality of life.
Causes & Symptoms
Clinical Causes: Genetic mutation in the IDUA gene Inheritance pattern: autosomal recessive (both parents must carry the gene mutation) Absence or deficiency of the enzyme alpha-L-iduronidase
Key Symptoms: Coarse facial features, such as a broad nose and enlarged tongue Hearing loss Clouding of the cornea Developmental delay in severe cases Joint stiffness and restricted movement Hepatosplenomegaly (enlarged liver and spleen) Cardiac issues, including valvular heart disease Respiratory problems, such as clicking or wheezing Bone abnormalities, including kyphosis and scoliosis Delayed growth and short stature
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, measuring enzyme activity levels in blood or skin cells, and genetic testing to identify mutations in the IDUA gene. Newborn screening may also detect the condition early. Imaging studies like X-rays can help identify characteristic skeletal abnormalities, and urine tests can detect excess mucopolysaccharides.
Treatment Protocols: Treatment options aim to manage symptoms and prevent complications. Enzyme replacement therapy (ERT) with laronidase can help reduce mucopolysaccharide buildup. Hematopoietic stem cell transplantation (bone marrow transplant) may be considered, especially in severe cases, to provide a source of cells producing the deficient enzyme. Supportive care includes physical therapy, surgical interventions for skeletal and cardiac issues, and regular monitoring for organ health. Early intervention is important for improving outcomes.
Clinical Advice & FAQs
Billing Guidance
Is E76.0 a billable ICD-10 code?
Yes, E76.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E76.0?
Clinical documentation must specify the nature of Mucopolysaccharidosis, type I and any associated comorbidities for accurate reporting.
Cite this Clinical Reference